Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

UCITS hedge funds down for year after tough June, commodities lone bright spot at +2.08%

Tuesday, July 05, 2011
Opalesque Industry Update - June happened to be a difficult month for most financial markets and hedge fund strategies. The UCITS Alternative Index Global is down -1.00%, bringing its year to date performance to -0.83% while the Fund of Funds Index is also down -1.35% reaching -1.52% since the beginning of the year. All strategies end the month with a negative performance. Emerging Markets and Commodities are the worst performing strategies with -1.69% and -1.50%. Fixed Income and Event-Driven are the best performing ones with -0.37% and -0.50%. On a year to date basis, the Commodities Index is still the best performer with 2.08%, followed by the Fixed Income Index with 0.95%. The CTA Index is the worst performer since the beginning of the year with -2.43%, followed by the Emerging Markets and FX Indices with both -1.72%.

Please find below the monthly performance of the UCITS Alternative Index as of June 2011.

Index

June

YTD

UCITS Alternative Index Global

-1.00%

-0.83%

UCITS Alternative Index Fund of Funds

-1.35%

-1.52%

UCITS Alternative Index Commodities

-1.50%

2.08%

UCITS Alternative Index CTA

-0.93%

-2.43%

UCITS Alternative Index Emerging Markets

-1.69%

-2.43%

UCITS Alternative Index Equity Market Neutral

-0.50%

-0.77%

UCITS Alternative Index Event Driven

-1.43%

-0.42%

UCITS Alternative Index Fixed Income

-0.37%

0.15%

UCITS Alternative Index FX

-1.02%

-1.15%

UCITS Alternative Index Long/Short Equity

-1.11%

-0.45%

UCITS Alternative Index Macro

-1.05%

-0.35%

UCITS Alternative Index Multi Strategy

-0.95%

0.29%

(press release) Source

kb

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for